PsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare Disorders
PARAMUS, NEW JERSEY, August 28, 2024 – PsychoGenics, a leader in AI-enabled phenotypic drug discovery, has been awarded a Fast Track...
Unlock New Possibilities with PsychoGenics’ Special Offer!
We’re excited to introduce more clients to our AI-enabled platforms through an exclusive promotion, available throughout the year. Offer Details:...
PsychoGenics Achieves Top Supplier Status on Scientist.com for 2023
PGI is pleased to be recognized by scientist.com as a top marketplace supplier for 2023.
PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric Disorders
PGI Drug Discovery LLC (PsychoGenics), a phenotypic drug discovery platform company, announced that it has entered into an exclusive license agreement with Roche to obtain global development, manufacturing, and commercialization rights…
PsychoGenics Launches Updated Corporate Identity and Brand
PsychoGenics, Inc. (“PsychoGenics” or the “Company”), the leading contract research organization (CRO) specializing in the central nervous system (CNS) focused preclinical and translational drug discovery services, is proud to unveil…
PsychoGenics and Collaborations Pharmaceuticals Awarded a $1M grant to Use AI Platforms to Design New Drugs for Mental Health Disorders
September 5, 2023, Paramus, New Jersey – PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are pleased to announce that...
PsychoGenics Highlights a Long-term Collaboration with the TSC Alliance on Rare Disease Day
Feb. 28, 2023 On this Rare Disease Day, we want to highlight and honor our long-term collaboration with the TSC...
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
Oct 11, 2022 · Business Wire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and...
PsychoGenics Strengthens Executive Team to Boost CNS Drug Discovery and CRO Capabilities
Biopharmaceutical Industry Veterans David Bleakman and Thomas Oakley Each Bring Three Decades of Experience to the Company Paramus, N.J., June...
PsychoGenics’ High Data Security Standards Are Certified by The NIH
PsychoGenics Inc. (PGI), a provider of AI-based phenotypic platforms and preclinical assays for the development of therapeutics for pain, neurodegenerative,...